Study guide
16.7 Menopausal Hormone Therapy
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
16.7 Menopausal Hormone Therapy
Key Takeaways Explain This Topic AI
Any patient with an intact uterus receiving systemic estrogen must also receive a progestogen, because unopposed estrogen causes endometrial hyperplasia and carcinoma.
The timing hypothesis holds that initiating therapy under age 60 or within 10 years of menopause carries a favorable risk-benefit profile.
Transdermal estrogen avoids hepatic first-pass metabolism and carries a lower venous thromboembolism and stroke risk than oral estrogen.
Low-dose vaginal estrogen for isolated genitourinary syndrome produces minimal systemic absorption and does not require a progestogen.
Absolute contraindications to systemic therapy include unexplained vaginal bleeding, estrogen-dependent breast or endometrial cancer, active or prior venous thromboembolism, active liver disease, and recent stroke or myocardial infarction.
Last updated: September 2026
Menopausal Hormone Therapy (MHT): Indications & Prescribing Principles
Menopausal Hormone Therapy (MHT), formerly referred to as Hormone Replacement Therapy (HRT), is the most effective treatment for menopausal symptoms.
Evidence-Based Clinical Indications (FDA & The Menopause Society / NAMS)
Moderate-to-Severe Vasomotor Symptoms (VMS): Hot flashes and night sweats disrupting sleep or daytime functioning.
Prevention of Postmenopausal Osteoporosis: In individuals at high risk of osteoporotic fractures who cannot tolerate or have contraindications to non-hormonal antiresorptive agents.
Treatment of Genitourinary Syndrome of Menopause (GSM): Local low-dose vaginal therapies are preferred for isolated GSM.
Premature Hypoestrogenism: In individuals with Premature Ovarian Insufficiency (POI) or surgical bilateral oophorectomy prior to age 45.
The "Timing Hypothesis" (The Window of Opportunity)
Extensive secondary analyses of the Women's Health Initiative (WHI) and prospective trials (such as the ELITE and KEEPS trials) firmly established the Timing Hypothesis :
Favorable Window: When MHT is initiated in individuals younger than 60 years of age OR within 10 years of menopause onset , the benefit-to-risk ratio is overwhelmingly favorable . In this early cohort, estrogen preserves vascular endothelial function, improves lipid profiles, reduces all-cause mortality, dramatically alleviates VMS, and reduces fracture risk without increasing coronary heart disease.
Late Initiation (>60 Years or >10–20 Years Postmenopause): Initiating systemic MHT in older individuals with established, subclinical atherosclerotic plaques confers harm. Estrogen can induce plaque instability and inflammatory degradation, significantly increasing the risks of coronary events, ischemic stroke, and venous thromboembolism. Core Architectural Principles of Menopausal Hormone Therapy
- ├── The Intact Uterus Decision Point (MANDATORY Uterine Protection Rule)
- │ ├── Intact Uterus Present ──> MUST prescribe Estrogen PLUS Progestin (EPT)
│ │ └── Unopposed estrogen causes endometrial hyperplasia & adenocarcinoma!
- │ └── Prior Hysterectomy (No Uterus) ──> Prescribe Estrogen ALONE (ET)
- │ └── Progestin is unnecessary and slightly increases breast cancer risk
- ├── Systemic Estrogen Delivery Modalities
- │ ├── Transdermal 17β-Estradiol (Patches, Gels, Sprays - Preferred First-Line)
- │ │ └── Bypasses hepatic first-pass metabolism; NO increase in VTE or stroke risk
- │ └── Oral Estrogen (Conjugated Equine Estrogens [CEE], Micronized Estradiol)
- │ └── Undergoes hepatic first-pass; induces clotting factors & increases VTE risk
- └── Progestin Selection for Uterine Protection
- ├── Micronized Progesterone (Prometrium 100–200 mg - Preferred)
- │ └── Metabolically neutral, breast-friendly, sedative (take at bedtime)
- ├── 52 mg Levonorgestrel IUD (LNG-IUD)
- │ └── Robust local endometrial suppression with minimal systemic absorption
- └── Synthetic Progestins (Medroxyprogesterone acetate [MPA])
[!CRITICAL] The Golden Rule of Menopausal Hormone Therapy:
Estrogen ALONE (ET) is prescribed EXCLUSIVELY for individuals who have undergone a hysterectomy (no uterus) .
Estrogen PLUS a Progestogen (EPT) (or Estrogen + Bazedoxifene) is MANDATORY for all individuals with an INTACT UTERUS . Prescribing systemic estrogen alone to a woman with a uterus produces continuous, unopposed endometrial cellular proliferation, resulting in a 6- to 8-fold increase in endometrial hyperplasia and endometrial adenocarcinoma . Concurrent progestogen halts mitosis, induces secretory transformation, and neutralizes this neoplastic risk!
Systemic Estrogen Routes: Transdermal vs. Oral
Transdermal 17β-Estradiol (Patches 0.025–0.1 mg/day, Gels, Sprays):
Mechanism: Absorbed directly across the dermis into the systemic venous circulation, completely bypassing hepatic first-pass metabolism .
Clinical Safety Profile: Does not stimulate hepatic synthesis of coagulation factors (Factor VII, VIII, prothrombin, fibrinogen) or Sex Hormone-Binding Globulin (SHBG). Large-scale observational studies and the ESTHER study confirm that transdermal estradiol confers NO statistically significant increase in the risk of Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or Ischemic Stroke .
Midwifery Indications: Preferred first-line formulation for all individuals, particularly those with obesity (BMI ≥30 kg/m²), tobacco use, mild controlled hypertension, hypertriglyceridemia, or gallbladder disease.
Oral Estrogens (Conjugated Equine Estrogens [CEE] 0.3–0.625 mg, Micronized Estradiol 0.5–2.0 mg):
Mechanism: Absorbed via the portal circulation and metabolized heavily by the liver.
Clinical Profile: Induces hepatic prothrombotic proteins and elevates serum triglycerides, conferring a small but real increase in the absolute risk of VTE (2- to 4-fold relative increase) and ischemic stroke. May increase the incidence of cholelithiasis.
Progestogen Formulations for Endometrial Protection
Micronized Progesterone (Prometrium, 100 mg daily continuous or 200 mg daily sequential for 12–14 days/month): Bioidentical to human ovarian progesterone. Highly preferred over synthetic progestins: lipid-neutral, does not elevate blood pressure, and observational cohorts (e.g., French E3N study) demonstrate a significantly more favorable breast safety profile compared to synthetic progestins. Patient counseling: Causes mild somnolence and relaxation due to neuroactive metabolites acting on GABA-A receptors; must be taken orally at bedtime .
Synthetic Progestins (Medroxyprogesterone Acetate [MPA] 2.5 mg daily continuous or 5–10 mg cyclic): Effective endometrial protection, but can blunt estrogen's positive HDL-raising effects. The WHI trial linked oral CEE + MPA with a slight elevation in invasive breast cancer risk after 4 to 5 years of continuous use (an effect largely driven by the synthetic progestin).
52 mg Levonorgestrel IUD (LNG-IUD): Excellent off-label endometrial protection when paired with oral or transdermal systemic estrogen, providing profound local mucosal atrophy with negligible systemic progestin levels.
Local Vaginal Estrogen Therapy for Isolated GSM
For patients presenting solely with genitourinary symptoms (vaginal dryness, dyspareunia, recurrent UTIs) without bothersome vasomotor hot flashes, local vaginal estrogen therapy is the undisputed treatment of choice .
Delivery Formulations: Low-dose estradiol vaginal tablets ( 10 mcg twice weekly), estradiol vaginal cream ( 0.5 to 1 g 2–3 times weekly), or an estradiol vaginal ring ( Estring , replaced every 90 days).
Physiologic Nuance: Extremely low therapeutic doses exert profound local trophic effects, restoring glycogen, lactobacilli, epithelial thickness, and acidic pH (<4.5), while serum estradiol concentrations remain entirely within the postmenopausal baseline reference range .
Board Exam Golden Fact: Low-dose local vaginal estrogen does NOT require concurrent progestogen administration , even in women with an intact uterus, because it does not induce systemic endometrial proliferation!
Absolute Contraindications to Systemic MHT
Systemic Menopausal Hormone Therapy must never be prescribed in the presence of:
Active or past personal history of Breast Cancer .
Active or suspected Estrogen-Dependent or Progestin-Dependent Malignancy (e.g., endometrial adenocarcinoma).
Unexplained, undiagnosed Abnormal Genital / Uterine Bleeding (must rule out cancer with endometrial biopsy first!).
Active or past Venous Thromboembolism (DVT or Pulmonary Embolism).
Active or recent Arterial Thromboembolic Disease (Myocardial Infarction, Stroke, TIA).
Severe, active Liver Disease or Hepatic Impairment (inability to metabolize steroids).
Known high-risk thrombophilia (e.g., Factor V Leiden homozygous, Antiphospholipid Syndrome).
Porphyria cutanea tarda .